Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other financing activities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other financing activities for 15 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 2050.0% to -$8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.3 million through Dec 2025, down 2866.67% year-over-year, with the annual reading at -$200000.0 for FY2025, 50.0% up from the prior year.
  • Other financing activities for Q4 2025 was -$8.6 million at Myriad Genetics, down from -$400000.0 in the prior quarter.
  • The five-year high for Other financing activities was $1.2 million in Q1 2021, with the low at -$8.6 million in Q4 2025.
  • Average Other financing activities over 4 years is -$1.8 million, with a median of $150000.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 2050.0% in 2025, while the deepest fall reached 2050.0% in 2025.
  • Over 4 years, Other financing activities stood at $1.2 million in 2021, then plummeted by 41.67% to $700000.0 in 2022, then plummeted by 157.14% to -$400000.0 in 2024, then plummeted by 2050.0% to -$8.6 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$8.6 million, -$400000.0, and $700000.0 for Q4 2025, Q4 2024, and Q3 2022 respectively.